IgE promotes type 2 innate lymphoid cells in murine food allergy

Burton, Oliver T.; Tamayo, Jaciel M.; Stranks, Amanda J.; Miller, S. L.; Koleoglou, Kyle J.; Weinberg, Ellen O.; Oettgen, Hans C.

doi:10.1111/cea.13075

Cited by 71 publications

(49 citation statements)

References 60 publications

(158 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In mouse models of food allergy, allergenderived, IgE-mediated, mediator release of mast cells leads to IL-13 secretion of ILC2, which enhances the sensitivity to these mediators. 47 Similarly, ILC2-derived IL-4 suppresses the induction of allergen-specific Tregs that are key in regulating ILC2 activation. 48 Recent data provide new evidence for regulatory properties.…”

Section: Novel Data On Clinical Markers and Biomarkers Of Food Allergymentioning

confidence: 99%

Recent developments and highlights in food allergy

Eiwegger

Hung

Diego

et al. 2019

Allergy

View full text Add to dashboard Cite

The achievement of long-lasting, safe treatments for food allergy is dependent on the understanding of the immunological basis of food allergy. Accurate diagnosis is essential for management. In recent years, data from oral food challenges have revealed that routine allergy testing is poor at predicting clinical allergy for tree nuts, almonds in particular. More advanced antigen-based tests including component-resolved diagnostics and epitope reactivity may lead to more accurate diagnosis and selection of therapeutic intervention. Additional diagnostic accuracy may come from cellular tests such as the basophil activation test or mast cell approaches. In the context of clinical trials, cellular tests have revealed specific T-cell and B-cell populations that are more abundant in food-allergic individuals with distinct mechanistic features.Awareness of clinical markers, such as the ability to eat baked forms of milk and egg, continues to inform the understanding of natural tolerance development.Mouse models have allowed for investigation into multiple mechanisms of food allergy including modification of epithelial metabolism, and the induction of regulatory cell subsets and the microbiome. Increasing numbers of children who underwent food immunotherapy enlarged the body of evidence on mechanisms and predictors of treatment success. Experimental immunological markers in conjunction with clinical determinants such as lower age and lower initial specific IgE appear to be of benefit.More research on the optimal dose, preparation, and route of application integrating a high-level safety and efficacy is demanded. Alternatively, biologics blocking TSLP, IL-33, IL-4 and IL-13, or IgE may help to achieve that. K E Y W O R D Sallergy treatment, biologics, food allergy, immune tolerance, immunotherapy | 2357 EIWEGGER Et al.

show abstract

Section: Novel Data On Clinical Markers and Biomarkers Of Food Allergymentioning

confidence: 99%

Recent developments and highlights in food allergy

Eiwegger

Hung

Diego

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…Considering their potent ability to secrete cytokines, it is not surprising that ILC2s have been shown to contribute to the development of allergic inflammation in well-established animal models of airway inflammation, including those initiated by HDM extracts, papain, Alternaria alternata antigens, sensitization and challenge with OVA, as well as treatment with recombinant IL-33. Further, ILC2s are reported to contribute to murine models of food allergy and AD-like disease (28)(29)(30)(31). Consistent with these murine studies, ILC2s have been found to accumulate in tissue explants of patients suffering allergic conditions, such as asthma, allergic rhinitis, and AD (29,32,33).…”

Section: Type 2 Innate Lymphoid Cells (Ilc2s) Promote Allergic Inflammentioning

confidence: 55%

Contributions of innate lymphocytes to allergic responses

Inclan-Rico

Ponessa

Siracusa

2019

Current Opinion in Allergy &Amp; Clinical Immunology

View full text Add to dashboard Cite

Purpose of Review.-Allergic diseases represent a growing global health concern, especially among pediatric populations. Current strategies for the treatment of allergies and asthma focus on limiting the severity of the symptoms; however, additional research investigating the mechanisms promoting inflammation in the context of allergic reactions may lead to the development of more effective therapeutic strategies. Recent findings.-Novel studies have highlighted the contributions of innate lymphocytes to the induction of inflammatory responses to allergens. Remarkably, neuron-derived signals, hormones, and even vitamins have been suggested to modulate the activity of innate lymphocytes, opening new windows of opportunity for the treatment of allergic inflammation Summary.-These studies highlight the complex interactions of the nervous, endocrine and immune system that promote pathology in the context of allergic inflammation. Further studies are required to understand these interactions in order to aid in the development of novel and muchneeded therapies to treat allergic conditions.

show abstract

“…Surprisingly, the IgE molecule is (alone or in combination with activated mast cells) a potent promotor of intestinal ILC2 cells activity in murine model of food allergy. 44 …”

Section: The Role Of Ige In the Pathogenesis Of Bronchial Asthmamentioning

confidence: 99%

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Novosad

Krčmová

2020

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Bronchial asthma is a heterogeneous disease whose definition and treatment are based on evidence of variable airway obstruction and airway inflammation. Despite the enormous increase in the amount of information on the pathogenesis of this disease, diagnosis is still an unresolved problem, as we still lack sensitive and specific biomarkers. On the other hand, at the turn of the 20th and 21st century, there was a rapid development of therapeutic modalities based on the principle of biological therapy. The first authorized drug matching these characteristics was omalizumab – a monoclonal antibody directed against immunoglobulin E (IgE). It has been used for the treatment of severe forms of bronchial asthma for more than 15 years, which is a sufficient time to acquire ways of its effective use and to assess whether the treatment with omalizumab has met our expectations. However, we continue to discover new and surprising facts about the effects of omalizumab treatment which leads to widening of therapeutic indications. In this work, a basic overview of the very complex role of the IgE molecule in the organism (with a special emphasis on allergic asthma) is discussed, and the most important practical and clinical consequences resulting from its modulation by targeted therapy with omalizumab are summarized.

show abstract

IgE promotes type 2 innate lymphoid cells in murine food allergy

Cited by 71 publications

References 60 publications

Recent developments and highlights in food allergy

Recent developments and highlights in food allergy

Contributions of innate lymphocytes to allergic responses

Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?

Contact Info

Product

Resources

About